CONFERENCE CO-CHAIRS

Paul E. Oberstein, MD
Assistant Professor of Clinical Medicine
Division of Hematology/Oncology, Department of Medicine
Herbert Irving Comprehensive Cancer Center
Columbia University College of Physicians and Surgeons
NewYork-Presbyterian/Columbia University Medical Center

Dr. Paul Oberstein received his medical degree from the Ohio State University College of Medicine. He completed residency training in Internal Medicine at Temple University Hospital before coming to New York-Presbyterian Hospital/Columbia University Medical Center for fellowship training in Hematology/Oncology. After completing clinical training in Gastrointestinal Oncology under the mentorship of Dr. Alfred Neugut, he recently joined the faculty of Columbia University Medical Center where he is working with the Pancreas Center to develop novel clinical trials for patients with pancreatic cancer. Dr. Oberstein is conducting translational research in the lab of Dr. Kenneth Olive, utilizing mouse models to gain insights into the role of tumor stroma and differentiation in mediating chemotherapy resistance and outcomes in pancreatic cancer. He is also supported by a Young Investigator Award from the American Society of Clinical Oncology and is working closely with members of the Hebert Irving Comprehensive Cancer Center in order to bring exciting scientific discoveries to the clinic.

Kenneth P. Olive, PhD
Assistant Professor of Medicine and Pathology
Herbert Irving Comprehensive Cancer Center
Columbia University College of Physicians and Surgeons
NewYork-Presbyterian/Columbia University Medical Center

Dr. Kenneth Olive began his doctoral studies in 1998 with Tyler Jacks at the MIT Center for Cancer Research, investigating the neomorphic effects of mutant p53 in a mouse model of Li-Fraumeni Syndrome. While at MIT, he also helped develop a conditional mutant model of advanced lung adenocarcinoma. After graduating in 2005, Dr. Olive began a postdoctoral fellowship in the laboratory of David Tuveson at the University of Pennsylvania, later moving with the lab to the University of Cambridge in England. There he built a translational research facility for studying novel anticancer therapeutics in genetically engineered mouse models of pancreatic cancer. His studies into chemoresistance and the effects of Hh pathway inhibitors on drug delivery in pancreatic cancer were published in Science in 2009, and led to a Phase II clinical trial to evaluate the approach in patients with metastatic pancreatic cancer. Dr. Olive recently joined the faculty of the Columbia University Herbert Irving Comprehensive Cancer Center, where he is continuing his investigations into the response of pancreatic tumors to therapeutic interventions.
Timothy C. Wang, MD  
Dorothy L. and Daniel H. Silberberg Professor of Medicine  
Columbia University College of Physicians and Surgeons  
Chief, Division of Digestive and Liver Diseases  
NewYork-Presbyterian/Columbia University Medical Center

Dr. Wang was born in Allentown, Pennsylvania, and lives in New York City. He received his medical degree from the Columbia College of Physicians and Surgeons (1983). He completed a residency in internal medicine at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis (1983-1986). Following clinical and research fellowships at Harvard Medical School and Massachusetts General Hospital (1986-1989), he joined the faculty there, first as an Assistant Professor and then as Associate Professor of Medicine and Associate Division Chief of the Gastrointestinal Unit until 2000. Dr. Wang then moved to the University of Massachusetts Medical School as the Gladys Smith Martin Professor of Medicine, Chief of the Division of Gastroenterology, and Director of Gastrointestinal Cancer. Dr. Wang returned to New York City in 2004, at which time he assumed the role of Chief of the Division of Digestive and Liver Diseases at NewYork-Presbyterian/Columbia University Medical Center (2004) and the Dorothy L. and Daniel H. Silberberg Professor of Medicine at Columbia University College of Physicians and Surgeons. An active basic investigator with multiple NIH grants, Dr. Wang’s research interests have focused on the role of inflammation and stem cells in gastrointestinal carcinogenesis. A world authority on stomach cancer, and a leader at Columbia University of the tumor microenvironment program, Dr. Wang has published over 220 original, peer-reviewed papers, as well as numerous reviews and chapters.

CONFERENCE FACULTY

Teresa A. Brentnall, MD  
Professor  
Division of Gastroenterology  
University of Washington Medical Center

Dr. Brentnall received her undergraduate training at Virginia Tech, and attended medical school at the University of Washington. She trained for her Medicine Residency at UCLA and returned to the University of Washington where she finished a fellowship in Gastroenterology. She has remained at the University of Washington since that time, where she holds the Walters Endowed Chair as a Professor in Medicine and an Adjunct Professor of Pathology. Her research is mainly translational and focuses on the earlier detection of pancreatic cancer using molecular biomarkers and molecular imaging. Dr. Brentnall is the head of the Pancreatic Cancer Surveillance program at the University of Washington which manages the endoscopic surveillance of high-risk individuals who inherit Familial Pancreatic Cancer (FPC). Her research team discovered that a germline mutation in Palladin, an embryonic and cytoskeletal protein, causes Familial Pancreatic Cancer in one rare FPC kindred and that palladin functions in cancer associated fibroblasts to aid in sporadic pancreatic cancer invasion. Dr. Brentnall is an Emeritus Scientific Advisory Board Member of the Pancreatic Cancer Action Network, and served as a
member of the NIH Pancreatic Cancer Progress Review Group. She was an Invited Panel member at the National Pancreatic Foundation Workshop on the Future of Research in Pancreatic Diseases in Baltimore, Maryland. Dr. Brentnall has had multiple pancreatic cancer grants funded through NCI.

**Eric Collisson, MD**  
Assistant Professor  
UCSF School of Medicine

Eric Collisson, MD, is a medical oncologist with a clinical interest in gastrointestinal malignancies and a research interest in genomics as it pertains to classifications of human cancer. He received his medical degree at UC Los Angeles, completed an internship and residency in Internal Medicine at Stanford University Hospital followed by a Medical Oncology fellowship at UC San Francisco. He is currently an assistant professor in the Department of Medicine at UCSF in the Division of Hematology/Oncology.

**Howard C. Crawford, PhD**  
Associate Professor  
Department of Cancer Biology  
Mayo Clinic Cancer Center

Dr. Howard Crawford received his PhD from UT Southwestern in 1993 and trained as a postdoctoral fellow at Vanderbilt University with Dr. Lynn Matrisian. The focus of his research is on the role of MMP and ADAM metalloproteinases in pancreatic tumorigenesis and tumor progression, which has led to an ongoing reassessment of the proteinase dependent roles of the EGFR and Notch signal transduction pathways in these processes. Dr. Crawford currently holds the position of Associate Professor at the Mayo Clinic Florida.

**Robert L. Fine, MD**  
Herbert Irving Associate Professor of Medicine, Division of Medical Oncology  
Herbert Irving Comprehensive Cancer Center  
Columbia University College of Physicians and Surgeons  
Director, Medical Oncology, The Pancreas Center  
Director of Experimental Therapeutics  
NewYork-Presbyterian/Columbia University Medical Center

Dr. Robert Fine, Director of the Experimental Therapeutics Program at NewYork-Presbyterian Hospital and the Herbert Irving Associate Professor of Medicine at Columbia University Medical Center, is the perfect example of a physician who consistently excels in his research and who provides exceptional patient care. He received his M.D. degree from the University of Chicago, served a medical residency at Stanford University, and had a fellowship in medical oncology at the National Cancer Institute (NCI). Before joining NewYork-Presbyterian/Columbia, Dr. Fine was on the faculty of NCI and Duke University School of Medicine. He is currently listed as one of the top three pancreatic cancer specialists in the U.S. consecutively from 2005 – now in the Best Doctors issue by New York Magazine and one of the top doctors in the U.S. Medical Oncology field.
Dr. Fine studies the development and pharmacology of novel anticancer agents. The advances he has made in his research translate into new treatments and therapies for those patients who often are not provided options at other institutions. His laboratory findings have yielded cutting edge treatments of the most serious types of cancer, such as pancreatic, brain cancer and neuroendocrine cancers. He has developed the first successful chemotherapy treatments for DSRCT a highly fatal sarcoma of young adults, and a new therapy for pituitary cancers. These treatments are unique in that they were solely developed in Dr. Fine’s lab and have been very useful for these traditionally untreatable cancers. His lab also developed taxotere chemotherapy for metastatic, hormone refractory prostate cancer which is still the standard of care, in addition to the standard of care for the chemotherapy of metastatic cancers to the brain which occurs in over 200,000 cases/year in the U.S. Dr. Fine’s novel therapy of GTX has become the leading treatment for pancreatic cancer patients across the country and is quickly becoming the standard of care. GTX has one of the highest response and survival rates in the US and Europe. Dr. Fine also discovered another method to treat pancreatic cancer which takes the place of chemotherapy. In addition, he is investigating gene therapy approaches and is positioned to radically change the standard of care of metastatic and glioma brain tumors, based on studies he performed at NewYork-Presbyterian/Columbia. Finally a new treatment called CapTem for neuroendocrine cancers such as carcinoids and pancreatic neuroendocrine tumors which has the highest response rates in the U.S./Europe has been developed. CapTem, developed at The Pancreas Center at Columbia, is the first treatment which causes shrinkage of carcinoids at a rate over 35% and stable disease rates of 60%, while previous treatments had response rates less than 5% in carcinoid and other neuroendocrine cancers. Dr. Fine has changed the course of medicine with his determination and desire to find a cure.

**Tamas A. Gonda, MD**
Assistant Professor of Clinical Medicine
Columbia University College of Physicians and Surgeons
NewYork-Presbyterian/Columbia University Medical Center

Dr. Gonda’s primary research focus is the study of epigenetic alterations in gastric, esophageal and pancreatic cancer. He is especially interested in the use of DNA methylation changes as markers of pre-malignant disease and the potential of DNA methylation modifiers in (chemo) prevention and treatment of these neoplasms. His clinical research interests and practice as a therapeutic endoscopist are focused on the diagnosis and endoscopic treatment of esophageal and pancreato-biliary malignancies and pre-cancerous conditions.

**Matthias Hebrok, PhD**
Director, UCSF Diabetes Center
Hurlbut-Johnson Distinguished Professor in Diabetes Research
Department of Medicine
University of California, San Francisco (UCSF)

Matthias Hebrok, PhD is the *Hurlbut-Johnson Distinguished Professor in Diabetes Research* and Director of the UCSF Diabetes Center. He is the recipient of several honors and awards, including the JDRF Scholar Award. He received his Diploma degree in cellular biology from Albert-Ludwigs University in Freiburg, Germany, and performed his PhD thesis at the Max-
Planck-Institute for Immunobiology. His postdoctoral research was performed at HHMI at Harvard University. His laboratory uses Cell, Molecular, and Developmental Biology tools to decipher the mechanisms that underlie mammalian pancreas organogenesis and pancreatic diseases, including diabetes and pancreatic cancer. The goals of these studies are a) to generate functional β-cells from human stem cell populations for cell therapy purposes and b) to prevent the formation and growth of pancreatic tumors. Dr. Hebrok has served on numerous Grant Review Committees for the JDRF and NIH and is currently a full member of the NIH Cellular Aspects of Diabetes and Obesity (CADO) study section. He was a Member of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Diabetes Mellitus Interagency Coordinating Committee (DMICC) and continues to participate as Member of the Scientific Advisory Board for the Speman Graduate School at the Albert-Ludwigs University in Freiburg, Germany.

Sunil R. Hingorani, MD, PhD
Associate Member
Fred Hutchinson Cancer Research Center

Dr. Hingorani is a medical oncologist and cancer biologist specializing in pancreas cancer. He is Associate Member with joint appointments in the Clinical Research and Public Health Sciences Divisions at the Fred Hutchinson Cancer Research Center (FHCRC), and Associate Professor in the Department of Medicine, Division of Medical Oncology at the University of Washington (UW) School of Medicine. He is the Founding Director of the Pancreas Cancer Specialty Clinic (PCSC) at the Seattle Cancer Care Alliance (SCCA), a multidisciplinary clinic which is the focal point for a comprehensive translational research program in pancreas cancer, the Center for Accelerated Translation in Pancreas Cancer (CATPAC), which he also directs. The Hingorani laboratory studies the molecular and cellular origins of pancreas cancer primarily through the use of genetically engineered mouse models. These animal models of distinct genetic subtypes of pancreas cancer form the basis for an integrated, systematic and multidisciplinary program of study. The ultimate goal of these efforts is to identify and rapidly move to the clinic effective strategies for: 1) early detection; 2) chemoprevention; and 3) targeted therapies for invasive and metastatic disease.

Michael A. Hollingsworth, PhD
Professor and Director, Pancreatic Cancer Research
Eppley Institute for Research in Cancer & Allied Diseases
University of Nebraska Medical Center

Dr. Hollingsworth received his PhD from the Bowman Gray School of Medicine of Wake Forest University in 1982, followed by a postdoctoral fellowship with Richard Metzgar at Duke University from 1982-1986. He was a member of the faculty of the Department of Immunology at Duke from 1987-1991, and joined the faculty of the Eppley Institute in 1991, where he has led the group effort in pancreatic cancer research. Dr. Hollingsworth has worked on basic research projects in pancreatic cancer that investigate the biology of disease progression. Translational research efforts seek to identify potential biomarkers of disease presence, progression, and response to therapy, and to develop and test novel therapeutic strategies for treating pancreatic cancer. He serves as the Principal Investigator of a SPORE in GI and Pancreas Cancer, is PI of
an Early Diagnostic Research Network (EDRN) Biomarker Discovery Laboratory (U01) that focuses on biomarkers for pancreatic cancer, and is project leader and core director of a U54 Tumor Microenvironment Network Grant. He has served on numerous review panels at the NIH and for other granting agencies, including recent service (2011-12) as Chair of the Cancer Biomarkers Study Section (CBSS). He is a member of the Center for Scientific Review Advisory Council, and currently serves as a member of the Gastrointestinal Steering Committee and the Pancreas Cancer Task Force, which is organized by the Coordinating Center for Clinical Trials at the National Cancer Institute.

**Ralph H. Hruban, MD**  
Professor of Pathology and Oncology  
Director, Division of Gastrointestinal and Liver Pathology  
Director, Sol Goldman Pancreatic Cancer Research Center  
The Johns Hopkins University School of Medicine

Ralph H. Hruban, MD is a Professor of Pathology and Oncology at the Johns Hopkins University School of Medicine. He received his Doctor of Medicine from the Johns Hopkins University. He continued at Johns Hopkins for his residency training, and spent one year as a Fellow at Memorial Sloan-Kettering Cancer Center in New York. He returned to Johns Hopkins to join the Faculty in 1990, and rose to the rank of full professor in 1999. Dr. Hruban is currently the Director of The Sol Goldman Pancreatic Cancer Research Center at the Johns Hopkins University School of Medicine. His research focuses on familial pancreatic cancer, and on the precursor lesions that give rise to invasive pancreatic cancer. In addition to his research efforts, he helped create the Johns Hopkins Pancreatic Cancer Web Page, [http://pathology.jhu.edu/pancreas](http://pathology.jhu.edu/pancreas), and he led the team that developed a novel pancreatic pathology teaching application for the iPAD.

**Kimberly Kelly, PhD**  
Associate Professor of Biomedical Engineering and Robert Berne Cardiovascular Research Center  
University of Virginia

Kimberly A. Kelly, PhD is an Associate Professor of Biomedical Engineering at the University of Virginia in Charlottesville, VA. Dr. Kelly’s research interests include the identification of biomarkers and development of molecularly targeted imaging agents for the detection of various cancer disease processes. For example, through phage display screening, Dr. Kelly identified and validated plectin-1 as a novel biomarker for pancreatic ductal adenocarcinoma, a disease with less than a 5% 5 year survival rate. Further, she has developed a clinically relevant SPECT based imaging agent that will hopefully allow the detection of both primary and metastatic pancreatic cancer.
Andrew D. Rhim, MD
Assistant Professor of Internal Medicine
Assistant Director for Translational Research
Division of Gastroenterology, Department of Internal Medicine
Pancreas Multidisciplinary Program, University of Michigan Comprehensive Cancer Center
University of Michigan School of Medicine

The Rhim laboratory is focused on the biology of pre-cancerous lesions of epithelial organs and the molecular and cellular events that occur during their transition to cancer. We employ unique genetically engineered mouse models of pancreatic ductal adenocarcinoma (PDAC) as a model for cancer development and progression. The overarching goal of these studies is to learn more about how cancer evolves so that we may devise new strategies for early diagnosis and treatment for patients with clinically occult advanced precancerous lesions and early forms of cancer. Three themes underscore my work: 1) Identifying the key molecular events that drive the development and progression of precancerous lesions of the pancreas; 2) Dissecting and contrasting the interactions between the epithelium and the inflammatory stromal compartment during pancreatic disease, including early cancer; and 3) Understanding the mechanism and clinical implications of blood-borne dissemination and distant organ seeding of pancreatic epithelial cells, an unexpectedly early event during the transition from pre-cancer to cancer in multiple organs. We also are conducting prospective clinical trials to test the utility of biomarker candidates identified in our mouse models to predict subsequent tumor formation in patients at high-risk for carcinoma.

Gloria H. Su, PhD
Associate Professor at CUMC (in Pathology and OTO/HNS)
Columbia University College of Physicians and Surgeons
NewYork-Presbyterian/Columbia University Medical Center

After receiving her PhD in Immunology from University of Chicago, Dr. Su relocated to Johns Hopkins University where she first completed a postdoctoral fellowship in Cancer Genetics/Pancreatic Cancer. She then became an Instructor in the Department of Pathology and, in 2001, was promoted to Assistant Professor. In 2003, she joined Columbia University College of Physicians and Surgeons as an Assistant Professor in the Departments of Otolaryngology/Head & Neck Surgery, and Pathology. Her research interests include genetic profiling and mouse modeling for pancreatic cancer. Her research highlights include recognizing the importance of wild-type Kras in the context of oncogenic Kras, identification of the PI3K signaling dysregulation in IPMN, and the development of novel mouse models that simulate human PanIN or IPMN to invasive cancer. Dr. Su serves on the Board of The Pancreas Center at the CUMC, is the editor of Pancreatic Cancer: Methods and Protocols, and has served as a grant reviewer for the National Institutes of Health, Department of Defense – Congressionally Directed Medical Research Programs, Italian Ministry of Health, Qatar National Research Fund, and Cancer Council NSW Australia.
Margaret A. Tempero, MD
Director, UCSF Pancreas Center
Rombauer Family Distinguished Professorship in Pancreas Cancer Clinical and Translational Science
Professor of Medicine, Division of Hematology and Oncology, Department of Medicine
UCSF Helen Diller Family Comprehensive Cancer Center

Dr. Tempero is Director, UCSF Pancreas Center and Leader, Pancreas Cancer Program at the Helen Diller Family Comprehensive Cancer Center (HDFCCC). Her research career has focused on pancreatic ductal adenocarcinoma especially in the area of investigational therapeutics. She was a pioneer in the use of antibody-based therapies and helped develop the fixed dose rate concept for gemcitabine. Her group has developed effective gemcitabine combinations and provided a foundation for using CA19-9 as a surrogate for survival in clinical trials. Currently her group is assessing molecular subtypes and molecular enrichment for selecting new drugs for clinical evaluation.

Dr. Tempero recently served on the Oncology Drug Advisory Committee for the FDA. She served as Deputy Director and Interim Director for the UNMC Eppley Cancer Center until 1999, Chief Emeritus of the Division of Medical Oncology at UCSF (2000 – 2007) and Deputy Director and Director of Research Programs at the UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC) from 2000 to 2012.